Top

Published in:

01-04-2011 | Brief Report

Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy

Authors: Valentina Silvestri, Piera Rizzolo, Mario Falchetti, Ines Zanna, Giovanna Masala, Simonetta Bianchi, Domenico Palli, Laura Ottini

Published in: Breast Cancer Research and Treatment | Issue 2/2011

Abstract

Breast cancer (BC) in men is rare compared with BC in women, but its incidence is increasing along with attention toward this uncommon disease. Although with some differences, male and female BC share similar genetic predisposition factors, including BRCA1/2, CHEK2, and PALB2 mutations. As other BRCA1/2 functionally related DNA repair genes, such as CHEK2 and PALB2, BRIP1 is considered a moderate-penetrance BC susceptibility gene. At present, the role of BRIP1 on BC susceptibility in men is unknown. In this study, we aimed to assess whether BRIP1 variants may contribute to male BC (MBC) risk, by screening 97 MBC cases, all negative for BRCA1/2, CHEK2, and PALB2 mutations, selected from a population-based series of 126 MBCs from Central Italy. A total of five BRIP1 germ-line sequence alterations, three coding, and two non-coding variants, were detected in our series. The two non-coding variants IVS4-28G > A and 3′UTR 4049C > T were classified as neutral by in silico analysis. Of the three coding variants, one was a silent variant (E879E) and two resulted in amino acid substitution (R264W and P919S) showing a putative pathogenic role by in silico analysis. However, further analysis of tumor-associated loss of heterozygosity and the frequency of variant alleles, tested in 203 male population controls, suggested a neutral effect for both of these variants. Overall, our results indicate that BRIP1 variants may not play a relevant role in MBC predisposition.

Cantor SB, Bell DW, Ganesan S et al (2001) BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell 105(1):149–160PubMedCrossRef

Levran O, Attwooll C, Henry RT et al (2005) The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet 37(9):931–933PubMedCrossRef

Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8(10):735–748PubMedCrossRef

Walsh T, King MC (2007) Ten genes for inherited breast cancer. Cancer Cell 11(2):103–105PubMedCrossRef

Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 38(11):1239–1241PubMedCrossRef

Cantor S, Drapkin R, Zhang F et al (2004) The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA 101(8):2357–2362PubMedCrossRef

Sigurdson AJ, Hauptmann M, Chatterjee N et al (2004) Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer 4:9PubMedCrossRef

Guénard F, Labrie Y, Ouellette G et al (2008) Mutational analysis of the breast cancer susceptibility gene BRIP1/BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families. J Hum Genet 53(7):579–591PubMedCrossRef

Cao AY, Huang J, Hu Z et al (2009) Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat 115(1):51–55PubMedCrossRef

10.

Karppinen SM, Vuosku J, Heikkinen K, Allinen M, Winqvist R (2003) No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer 39(3):366–371PubMedCrossRef

11.

Fentiman IS, Fourquet A, Hortobagyi GN (2006) Male breast cancer. Lancet 367(9510):595–604PubMedCrossRef

12.

Speirs V, Shaaban AM (2009) The rising incidence of male breast cancer. Breast Cancer Res Treat 115(2):429–430PubMedCrossRef

13.

Brinton LA, Richesson DA, Gierach GL et al (2008) Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100(20):1477–1481PubMedCrossRef

14.

Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A (2010) Male breast cancer. Crit Rev Oncol Hematol 73(2):141–155PubMedCrossRef

15.

Meijers-Heijboer H, van den Ouweland A, Klijn J et al (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31(1):55–59PubMedCrossRef

16.

Ding YC, Steele L, Kuan CJ, Greilac S, Neuhausen SL (2010) Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States. Breast Cancer Res Treat. doi:10.1007/s10549-010-1195-2

17.

Neuhausen S, Dunning A, Steele L et al (2004) Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer 108(3):477–478PubMedCrossRef

18.

Ottini L, Rizzolo P, Zanna I et al (2009) BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. Breast Cancer Res Treat 116(3):577–586PubMedCrossRef

19.

Falchetti M, Lupi R, Rizzolo P et al (2008) BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat 110(1):161–167PubMedCrossRef

20.

Silvestri V, Rizzolo P, Zanna I et al (2010) PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat 122(1):299–301PubMedCrossRef

21.

Lewis AG, Flanagan J, Marsh A et al (2005) Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res 7(6):R1005–R1016PubMedCrossRef

22.

De Nicolo A, Tancredi M, Lombardi G et al (2008) A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function. Clin Cancer Res 14(14):4672–4680PubMedCrossRef

23.

Ray AM, Zuhlke KA, Johnson GR et al (2009) Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families. Br J Cancer 101(12):2043–2047PubMedCrossRef

24.

Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742PubMedCrossRef

25.

Erkko H, Xia B, Nikkila J et al (2007) A recurrent mutation in PALB2 in Finnish cancer families. Nature 446(7133):316–319PubMedCrossRef

26.

Luo L, Lei H, Du Q et al (2002) No mutations in the BACH1 gene in BRCA1 and BRCA2 negative breast-cancer families linked to 17q22. Int J Cancer 98(4):638–639PubMedCrossRef

27.

Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H (2006) BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer 6:19PubMedCrossRef

Title: Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy
Authors: Valentina Silvestri
Piera Rizzolo
Mario Falchetti
Ines Zanna
Giovanna Masala
Simonetta Bianchi
Domenico Palli
Laura Ottini
Publication date: 01-04-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1289-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2011

A gene expression signature identifies two prognostic subgroups of basal breast cancer

MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study

Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis

Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer

Effects on survival of menstrual cycle phase of adjuvant surgical oophorectomy in premenopausal women with breast cancer

Dietary glycemic index, glycemic load, and risk of breast cancer: meta-analysis of prospective cohort studies

Keynote webinar | Spotlight on antibody–drug conjugates in cancer